Bixiye
QP60-23 Commercial Pharmacy Benefit Exclusion for Elfabrio®, Vyjuvek™
Taariikhda dhaqangalka Barnaamijka: Jul 12, 2023
Natiijooyinka Raadinta
Soo bandhiga 1011 - 1020 ee natiijooyinka 4226
Bixiye
QP61-23 MHCP Pharmacy Benefit Exclusion for Elfabrio®, Epkinly™, and Vyjuvek™
Taariikhda dhaqangalka Barnaamijka: Jul 12, 2023
Bixiye
QP62-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2023
Taariikhda dhaqangalka Barnaamijka: Jul 12, 2023
Bixiye
QP63-23 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective August 1, 2023
Taariikhda dhaqangalka Barnaamijka: Jul 12, 2023
Bixiye
QP64-23 Medical Drug Update for New to Market Valoctocogene Roxaparvovec (Roctavian, f.k.a. Valrox)
Taariikhda dhaqangalka Barnaamijka: Jul 12, 2023
Macluumaadka Maaliyadda
Bixiye
commercial-em-007-critical-care-services.pdf
Bixiye
P47R1-23 MHCP Enrollment for Managed Care Organization (MCO) In-network Only Providers
Taariikhda dhaqangalka Barnaamijka: Jul 03, 2023
Bixiye
P48-23 Additional Records Received After Due Date
Taariikhda dhaqangalka Barnaamijka: Jul 03, 2023
Bixiye
P49-23 Minnesota Health Care Programs (MHCP) Operations Transition: New ID Numbers for MHCP Members
Taariikhda dhaqangalka Barnaamijka: Jul 03, 2023